ICU sedation, delirium & recovery
Timely Cessation of Proton Pump Inhibitors in Critically Ill Patients Impacts Morbidity and Mortality: A Propensity Score-Matched Cohort Study*
Authors' conclusion
These data demonstrate that an unnecessary continuation of PPI therapy after hospital discharge may significantly impact morbidity and mortality.
Study context
- Population
- ICU patients on German ICUs (2017–2018) who received PPI therapy for the first time during their index ICU stay without an indication for its continuation591,207 datasets screened
- Participants
- 11,576 patients
- Exposure
- Continued PPI vs No further PPI
- Continued PPIn = 4,825
- Outcome
- Frequency of predescribed adverse events associated with PPI therapy, 1-year rehospitalization rate, and 2-year mortality
Methodological detailspropensity score-matched, nationwide, 2-year follow-up
- Propensity score-matched
- Nationwide
- 2-year follow-up
Main finding
As reported in the abstract
Continued PPI
41.7%
4,825
Continued PPI vs No further PPIEstimate (95% CI)P value
Pneumonia
OR 1.27(1.15–1.39)
P < 0.001Cardiovascular events
OR 1.17(1.08–1.26)
P < 0.001Rehospitalization
OR 1.34(1.23–1.47)
2-year mortality
HR 1.17(1.08–1.27)
P = 0.006Observational data: associations, not effects.
Original publication
Timely Cessation of Proton Pump Inhibitors in Critically Ill Patients Impacts Morbidity and Mortality: A Propensity Score-Matched Cohort Study*. Crit Care Med. Published 19 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →